Normative Data for Macular Thickness by High-Definition Spectral-Domain Optical Coherence Tomography (Spectralis)
Purpose To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease. Design Prospective, observational study in an academic institutional setting. Methods Fifty subjects (age range, 20 to 84 years) with no k...
Saved in:
Published in: | American journal of ophthalmology Vol. 148; no. 2; pp. 266 - 271 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York, NY
Elsevier Inc
01-08-2009
Elsevier Elsevier Limited |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Purpose To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease. Design Prospective, observational study in an academic institutional setting. Methods Fifty subjects (age range, 20 to 84 years) with no known retinal disease, best-corrected visual acuity 20/20, and normal intraocular pressure were enrolled. The subjects were divided into 3 age groups: group 1 included subjects 20 to 40 years of age; group 2 included subjects 41 to 60 years of age; and group 3 included subjects 61 years of age and older. All subjects underwent a complete ophthalmologic examination to rule out any retinal diseases or glaucoma. All the OCT scans were performed by a single operator, and data obtained from the right eyes were analyzed by default, unless the right eye did not meet the inclusion criteria, and then data from left eyes were analyzed (n = 4). Central point thickness (CPT) and retinal thickness (RT) in 9 Early Treatment Diabetic Retinopathy Study (ETDRS) subfields, including central subfield (CSF), were analyzed. Statistical analyses were carried out using the analysis of variance. Results Overall, the mean CPT was 227.3 ± 23.2 μm, and mean CSF was 270.2 ± 22.5 μm. Among the ETDRS subfields, the outer nasal quadrant had the maximum thickness (mean ± standard deviation, 339.5 ± 16.9 μm). The RT did not show significant difference with age ( P = .62) or with gender ( P = .1). However, there was a suggestion of significant difference in RT of Black subjects as compared with White subjects ( P = .007) in the present study. Conclusions Normative values for macular thickness in otherwise healthy eyes were measured to be 227.3 μm (CPT) and 270.2 μm (CSF) using commercially available Spectralis SD-OCT. Based on the data, the present study proposes the guidelines for normal CSF thickness to be 315 μm for future studies using macular thickness measurements with Spectralis SD-OCT (Heidelberg Engineering, Vista, California, USA). |
---|---|
AbstractList | PURPOSETo establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease.DESIGNProspective, observational study in an academic institutional setting.METHODSFifty subjects (age range, 20 to 84 years) with no known retinal disease, best-corrected visual acuity 20/20, and normal intraocular pressure were enrolled. The subjects were divided into 3 age groups: group 1 included subjects 20 to 40 years of age; group 2 included subjects 41 to 60 years of age; and group 3 included subjects 61 years of age and older. All subjects underwent a complete ophthalmologic examination to rule out any retinal diseases or glaucoma. All the OCT scans were performed by a single operator, and data obtained from the right eyes were analyzed by default, unless the right eye did not meet the inclusion criteria, and then data from left eyes were analyzed (n = 4). Central point thickness (CPT) and retinal thickness (RT) in 9 Early Treatment Diabetic Retinopathy Study (ETDRS) subfields, including central subfield (CSF), were analyzed. Statistical analyses were carried out using the analysis of variance.RESULTSOverall, the mean CPT was 227.3 +/- 23.2 microm, and mean CSF was 270.2 +/- 22.5 microm. Among the ETDRS subfields, the outer nasal quadrant had the maximum thickness (mean +/- standard deviation, 339.5 +/- 16.9 microm). The RT did not show significant difference with age (P = .62) or with gender (P = .1). However, there was a suggestion of significant difference in RT of Black subjects as compared with White subjects (P = .007) in the present study.CONCLUSIONSNormative values for macular thickness in otherwise healthy eyes were measured to be 227.3 microm (CPT) and 270.2 microm (CSF) using commercially available Spectralis SD-OCT. Based on the data, the present study proposes the guidelines for normal CSF thickness to be 315 microm for future studies using macular thickness measurements with Spectralis SD-OCT (Heidelberg Engineering, Vista, California, USA). Purpose To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease. Design Prospective, observational study in an academic institutional setting. Methods Fifty subjects (age range, 20 to 84 years) with no known retinal disease, best-corrected visual acuity 20/20, and normal intraocular pressure were enrolled. The subjects were divided into 3 age groups: group 1 included subjects 20 to 40 years of age; group 2 included subjects 41 to 60 years of age; and group 3 included subjects 61 years of age and older. All subjects underwent a complete ophthalmologic examination to rule out any retinal diseases or glaucoma. All the OCT scans were performed by a single operator, and data obtained from the right eyes were analyzed by default, unless the right eye did not meet the inclusion criteria, and then data from left eyes were analyzed (n = 4). Central point thickness (CPT) and retinal thickness (RT) in 9 Early Treatment Diabetic Retinopathy Study (ETDRS) subfields, including central subfield (CSF), were analyzed. Statistical analyses were carried out using the analysis of variance. Results Overall, the mean CPT was 227.3 ± 23.2 μm, and mean CSF was 270.2 ± 22.5 μm. Among the ETDRS subfields, the outer nasal quadrant had the maximum thickness (mean ± standard deviation, 339.5 ± 16.9 μm). The RT did not show significant difference with age ( P = .62) or with gender ( P = .1). However, there was a suggestion of significant difference in RT of Black subjects as compared with White subjects ( P = .007) in the present study. Conclusions Normative values for macular thickness in otherwise healthy eyes were measured to be 227.3 μm (CPT) and 270.2 μm (CSF) using commercially available Spectralis SD-OCT. Based on the data, the present study proposes the guidelines for normal CSF thickness to be 315 μm for future studies using macular thickness measurements with Spectralis SD-OCT (Heidelberg Engineering, Vista, California, USA). To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease. Prospective, observational study in an academic institutional setting. Fifty subjects (age range, 20 to 84 years) with no known retinal disease, best-corrected visual acuity 20/20, and normal intraocular pressure were enrolled. The subjects were divided into 3 age groups: group 1 included subjects 20 to 40 years of age; group 2 included subjects 41 to 60 years of age; and group 3 included subjects 61 years of age and older. All subjects underwent a complete ophthalmologic examination to rule out any retinal diseases or glaucoma. All the OCT scans were performed by a single operator, and data obtained from the right eyes were analyzed by default, unless the right eye did not meet the inclusion criteria, and then data from left eyes were analyzed (n = 4). Central point thickness (CPT) and retinal thickness (RT) in 9 Early Treatment Diabetic Retinopathy Study (ETDRS) subfields, including central subfield (CSF), were analyzed. Statistical analyses were carried out using the analysis of variance. Overall, the mean CPT was 227.3 +/- 23.2 microm, and mean CSF was 270.2 +/- 22.5 microm. Among the ETDRS subfields, the outer nasal quadrant had the maximum thickness (mean +/- standard deviation, 339.5 +/- 16.9 microm). The RT did not show significant difference with age (P = .62) or with gender (P = .1). However, there was a suggestion of significant difference in RT of Black subjects as compared with White subjects (P = .007) in the present study. Normative values for macular thickness in otherwise healthy eyes were measured to be 227.3 microm (CPT) and 270.2 microm (CSF) using commercially available Spectralis SD-OCT. Based on the data, the present study proposes the guidelines for normal CSF thickness to be 315 microm for future studies using macular thickness measurements with Spectralis SD-OCT (Heidelberg Engineering, Vista, California, USA). To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease. Prospective, observational study in an academic institutional setting. Fifty subjects (age range, 20 to 84 years) with no known retinal disease, best-corrected visual acuity 20/20, and normal intraocular pressure were enrolled. The subjects were divided into 3 age groups: group 1 included subjects 20 to 40 years of age; group 2 included subjects 41 to 60 years of age; and group 3 included subjects 61 years of age and older. All subjects underwent a complete ophthalmologic examination to rule out any retinal diseases or glaucoma. All the OCT scans were performed by a single operator, and data obtained from the right eyes were analyzed by default, unless the right eye did not meet the inclusion criteria, and then data from left eyes were analyzed (n = 4). Central point thickness (CPT) and retinal thickness (RT) in 9 Early Treatment Diabetic Retinopathy Study (ETDRS) subfields, including central subfield (CSF), were analyzed. Statistical analyses were carried out using the analysis of variance. Overall, the mean CPT was 227.3 ± 23.2 μm, and mean CSF was 270.2 ± 22.5 μm. Among the ETDRS subfields, the outer nasal quadrant had the maximum thickness (mean ± standard deviation, 339.5 ± 16.9 μm). The RT did not show significant difference with age ( P = .62) or with gender ( P = .1). However, there was a suggestion of significant difference in RT of Black subjects as compared with White subjects ( P = .007) in the present study. Normative values for macular thickness in otherwise healthy eyes were measured to be 227.3 μm (CPT) and 270.2 μm (CSF) using commercially available Spectralis SD-OCT. Based on the data, the present study proposes the guidelines for normal CSF thickness to be 315 μm for future studies using macular thickness measurements with Spectralis SD-OCT (Heidelberg Engineering, Vista, California, USA). |
Author | Chalam, Kakarla V Grover, Sandeep Murthy, Ravi K Brar, Vikram S |
Author_xml | – sequence: 1 fullname: Grover, Sandeep – sequence: 2 fullname: Murthy, Ravi K – sequence: 3 fullname: Brar, Vikram S – sequence: 4 fullname: Chalam, Kakarla V |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21797660$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19427616$$D View this record in MEDLINE/PubMed |
BookMark | eNp9klFv0zAUhS00xLrBD-AFWUIgeEi5TmI70SQk1AJDGuxh5dmy3ZvVXRJ3djKp_x5HLUzaA0-Wpe9cH59zz8hJ73sk5DWDOQMmPm3neuvnOUA9h2IOIJ6RGatknbGqZidkBgB5Vhd1eUrOYtymq5ClfEFOWV3mUjAxI_e_fOj04B6QLvWgaeMD_ant2OpAVxtn73qMkZo9vXS3m2yJjevd4HxPb3Zoh6DbbOk77Xp6vRuc1S1d-A0G7C3Sle_8bdC7zZ5--Eu7-PEled7oNuKr43lOfn_7ulpcZlfX338svlxllhcwZAIY58YIwddVLRGb2lQVa0qL1hbS5AaNaKrSmqpsOGMlIEcsDaxN3kgBpjgn7w9zd8HfjxgH1blosW11j36MSkgOnOeQwLdPwK0fQ5-8KSZKDlBKJhPFDpQNPsaAjdoF1-mwVwzU1IbaqtSGmtpQUKiUddK8OU4eTYfrR8Ux_gS8OwI6pvCaoHvr4j8uZ7KWQkwWLw4cpsAeHAYVrZtCXruQglVr7_5r4_MTtW1TjenBO9xjfPytirkCdTOtzbQ1UEMayHjxB0Byvjw |
CODEN | AJOPAA |
CitedBy_id | crossref_primary_10_3233_JAD_231414 crossref_primary_10_1167_iovs_63_12_4 crossref_primary_10_1007_s10384_016_0486_5 crossref_primary_10_1016_j_oret_2020_09_023 crossref_primary_10_1097_IAE_0000000000002378 crossref_primary_10_5301_ejo_5000845 crossref_primary_10_4103_IJO_IJO_146_23 crossref_primary_10_1016_j_arr_2016_05_013 crossref_primary_10_1002_brb3_2592 crossref_primary_10_3928_15428877_20111222_02 crossref_primary_10_1186_s12886_016_0232_2 crossref_primary_10_1097_MD_0000000000005441 crossref_primary_10_1007_s13410_015_0362_8 crossref_primary_10_1371_journal_pone_0067265 crossref_primary_10_1007_s00417_014_2672_9 crossref_primary_10_1097_IAE_0b013e31820d3f13 crossref_primary_10_1007_s00417_018_4004_y crossref_primary_10_1538_expanim_22_0022 crossref_primary_10_1016_j_ajo_2010_06_034 crossref_primary_10_1167_iovs_64_13_24 crossref_primary_10_1016_j_ophtha_2012_05_018 crossref_primary_10_1016_j_ajo_2013_04_027 crossref_primary_10_1136_bmjopen_2017_016142 crossref_primary_10_1016_j_ajo_2013_04_026 crossref_primary_10_1016_j_survophthal_2017_05_006 crossref_primary_10_1016_j_ajo_2016_10_013 crossref_primary_10_1371_journal_pone_0037638 crossref_primary_10_3109_09273948_2013_871566 crossref_primary_10_1371_journal_pone_0216351 crossref_primary_10_1186_s12886_015_0019_x crossref_primary_10_3390_e23060699 crossref_primary_10_1016_j_oftal_2019_07_010 crossref_primary_10_1016_j_jfo_2018_09_005 crossref_primary_10_1097_IAE_0b013e3181cd4803 crossref_primary_10_1155_2019_1698967 crossref_primary_10_5301_ejo_5000869 crossref_primary_10_1007_s00417_022_05664_z crossref_primary_10_5005_jp_journals_10008_1165 crossref_primary_10_1016_j_ajo_2012_06_028 crossref_primary_10_1007_s00417_017_3681_2 crossref_primary_10_1177_1120672119880394 crossref_primary_10_1016_j_ophtha_2016_08_025 crossref_primary_10_18231_j_ijceo_2021_048 crossref_primary_10_1167_iovs_65_2_26 crossref_primary_10_4102_aveh_v74i1_300 crossref_primary_10_1007_s10384_011_0085_4 crossref_primary_10_3109_15569527_2014_950380 crossref_primary_10_1097_IAE_0000000000002696 crossref_primary_10_1097_APO_0000000000000153 crossref_primary_10_2147_OPTH_S257462 crossref_primary_10_3390_ijms241813932 crossref_primary_10_1007_s00417_018_3951_7 crossref_primary_10_4102_aveh_v78i1_482 crossref_primary_10_1007_s00417_021_05203_2 crossref_primary_10_1016_j_ajo_2012_11_029 crossref_primary_10_1016_j_exer_2017_09_001 crossref_primary_10_1007_s00417_012_2044_2 crossref_primary_10_1007_s00417_017_3617_x crossref_primary_10_1038_s41598_020_73645_5 crossref_primary_10_1016_j_ajo_2024_06_016 crossref_primary_10_1186_s40942_019_0178_7 crossref_primary_10_1167_tvst_9_5_24 crossref_primary_10_1186_s12886_018_0862_7 crossref_primary_10_21516_2072_0076_2020_13_2_99_104 crossref_primary_10_1038_s41598_020_79424_6 crossref_primary_10_1111_j_1755_3768_2012_02398_x crossref_primary_10_1136_bjophthalmol_2021_319587 crossref_primary_10_3928_23258160_20170329_01 crossref_primary_10_1007_s00417_018_3901_4 crossref_primary_10_1177_24741264231165611 crossref_primary_10_1016_j_ajo_2010_12_010 crossref_primary_10_1016_j_ophtha_2023_05_023 crossref_primary_10_1016_j_preteyeres_2017_04_003 crossref_primary_10_1097_IAE_0000000000001136 crossref_primary_10_1038_eye_2016_214 crossref_primary_10_1007_s00417_017_3749_z crossref_primary_10_1097_IAE_0000000000000847 crossref_primary_10_1007_s00417_021_05191_3 crossref_primary_10_1177_11206721231183471 crossref_primary_10_3390_jcm9103317 crossref_primary_10_5301_ejo_5000949 crossref_primary_10_1155_2018_1078531 crossref_primary_10_3928_15428877_20120424_01 crossref_primary_10_1007_s00417_016_3559_8 crossref_primary_10_1186_s40662_018_0119_9 crossref_primary_10_1016_j_ajo_2011_08_024 crossref_primary_10_1136_bmjopen_2016_012972 crossref_primary_10_6000_2292_2598_2020_08_02_20 crossref_primary_10_1111_opo_12321 crossref_primary_10_1097_OPX_0b013e3182186a36 crossref_primary_10_18632_oncotarget_10442 crossref_primary_10_1159_000450958 crossref_primary_10_1016_j_ophtha_2019_03_029 crossref_primary_10_1186_s12348_022_00314_1 crossref_primary_10_1364_BOE_7_000629 crossref_primary_10_1007_s10384_016_0460_2 crossref_primary_10_1186_s12886_020_01391_3 crossref_primary_10_1038_s42256_020_00247_1 crossref_primary_10_1016_j_nmd_2019_11_012 crossref_primary_10_1016_j_ophtha_2016_03_010 crossref_primary_10_18008_1816_5095_2022_4_705_718 crossref_primary_10_1111_j_1442_9071_2011_02593_x crossref_primary_10_1371_journal_pone_0276958 crossref_primary_10_1089_jop_2013_0010 crossref_primary_10_1177_1120672119899379 crossref_primary_10_1038_eye_2016_118 crossref_primary_10_1038_eye_2016_238 crossref_primary_10_4102_aveh_v76i1_374 crossref_primary_10_1016_j_ajo_2009_08_037 crossref_primary_10_1002_humu_22822 crossref_primary_10_1136_bjophthalmol_2013_304564 crossref_primary_10_1016_j_bj_2016_04_003 crossref_primary_10_1016_j_exer_2018_01_012 crossref_primary_10_1167_tvst_10_2_10 crossref_primary_10_3109_02713683_2014_952828 crossref_primary_10_1080_02713683_2021_1908566 crossref_primary_10_1007_s00417_010_1453_3 crossref_primary_10_1007_s00417_023_06086_1 crossref_primary_10_1016_j_exer_2019_107856 crossref_primary_10_1186_s40942_023_00459_8 crossref_primary_10_3389_fmed_2023_1275308 crossref_primary_10_1371_journal_pone_0253720 crossref_primary_10_5301_ejo_5000582 crossref_primary_10_1097_IAE_0000000000000239 crossref_primary_10_1016_j_ogla_2023_09_003 crossref_primary_10_1080_09273948_2022_2113806 crossref_primary_10_1186_s12886_018_0842_y crossref_primary_10_1007_s00417_019_04451_7 crossref_primary_10_1109_ACCESS_2020_2977355 crossref_primary_10_1136_bjo_2022_321766 crossref_primary_10_1016_j_ophtha_2009_12_014 crossref_primary_10_1007_s10633_013_9375_0 crossref_primary_10_1016_j_sjopt_2014_10_003 crossref_primary_10_1167_iovs_64_15_11 crossref_primary_10_3390_diagnostics13081377 crossref_primary_10_12659_MSM_893221 crossref_primary_10_1016_j_ajo_2010_07_026 crossref_primary_10_1016_j_oftale_2013_01_003 crossref_primary_10_1038_s41598_020_78059_x crossref_primary_10_1016_j_ajo_2014_08_039 crossref_primary_10_1016_j_survophthal_2020_03_002 crossref_primary_10_1371_journal_pone_0203324 crossref_primary_10_5301_ejo_5000904 crossref_primary_10_1007_s00417_016_3512_x crossref_primary_10_1016_j_ajo_2017_01_020 crossref_primary_10_3109_02713683_2015_1119854 crossref_primary_10_1371_journal_pone_0147782 crossref_primary_10_1186_1471_2415_10_13 crossref_primary_10_1136_bjophthalmol_2018_312349 crossref_primary_10_1097_j_jcrs_0000000000000226 crossref_primary_10_1080_09286586_2023_2251153 crossref_primary_10_1016_j_oftale_2019_07_006 crossref_primary_10_1016_j_pdpdt_2022_103131 crossref_primary_10_1371_journal_pone_0180450 crossref_primary_10_2147_OPTH_S272431 crossref_primary_10_36299_jkgs_2022_11_1_21 crossref_primary_10_5301_ejo_5000898 crossref_primary_10_1016_j_oftal_2013_01_005 crossref_primary_10_1016_j_ajo_2022_09_002 crossref_primary_10_1016_j_ajo_2011_01_027 crossref_primary_10_3389_fopht_2024_1372429 crossref_primary_10_1007_s00296_016_3593_1 crossref_primary_10_1016_j_parkreldis_2012_07_012 crossref_primary_10_1089_jop_2013_0214 crossref_primary_10_3390_jcm12123976 crossref_primary_10_1155_2015_715798 crossref_primary_10_1371_journal_pone_0111203 crossref_primary_10_1007_s00417_011_1708_7 crossref_primary_10_1007_s00417_018_4126_2 crossref_primary_10_1016_j_xops_2023_100386 crossref_primary_10_1097_IAE_0000000000003032 crossref_primary_10_1016_j_ajo_2014_01_020 crossref_primary_10_3928_15428877_20100430_02 crossref_primary_10_3892_etm_2017_4820 crossref_primary_10_3389_fneur_2019_01117 crossref_primary_10_1007_s00417_015_3075_2 crossref_primary_10_4103_2347_5617_164633 crossref_primary_10_1007_s10384_012_0192_x crossref_primary_10_1007_s00417_012_2173_7 crossref_primary_10_3928_23258160_20180221_01 crossref_primary_10_1016_j_ophtha_2012_07_048 crossref_primary_10_1167_iovs_18_25332 crossref_primary_10_31362_patd_428103 crossref_primary_10_3928_23258160_20121221_06 crossref_primary_10_4102_aveh_v75i1_330 crossref_primary_10_1016_j_exer_2016_05_013 crossref_primary_10_1186_s40942_020_00270_9 crossref_primary_10_1097_IJG_0b013e3182070cc6 crossref_primary_10_1371_journal_pone_0169520 crossref_primary_10_1016_j_ajo_2017_02_025 crossref_primary_10_12771_emj_2017_40_2_71 crossref_primary_10_3390_jcm10122659 crossref_primary_10_1080_13816810_2017_1401088 crossref_primary_10_1097_OPX_0b013e318251293a crossref_primary_10_1155_2014_865394 crossref_primary_10_1038_eye_2011_293 crossref_primary_10_1016_j_oret_2017_12_012 crossref_primary_10_1038_s41598_019_49816_4 crossref_primary_10_1016_j_ajo_2016_05_015 crossref_primary_10_1097_IAE_0000000000000464 crossref_primary_10_1007_s00417_017_3669_y crossref_primary_10_17925_USOR_2018_11_2_91 crossref_primary_10_1155_2013_434560 crossref_primary_10_3928_23258160_20170630_01 crossref_primary_10_1007_s00417_011_1630_z crossref_primary_10_1007_s10633_012_9367_5 |
Cites_doi | 10.1016/j.ophtha.2005.05.023 10.1016/S0161-6420(95)31032-9 10.1016/S0161-6420(13)38009-9 10.1097/00006982-200102000-00010 10.1016/j.ophtha.2007.04.052 10.1001/archopht.124.2.193 10.1177/112067210201200205 10.1126/science.1957169 10.1167/iovs.08-2113 10.1016/j.ophtha.2007.02.006 10.1016/j.ophtha.2006.05.046 10.1167/iovs.07-1000 10.1016/j.ophtha.2006.03.020 10.1167/iovs.08-1967 10.1001/archopht.1995.01100080071031 10.3928/1542-8877-20000501-04 |
ContentType | Journal Article |
Copyright | Elsevier Inc. 2009 Elsevier Inc. 2009 INIST-CNRS Copyright Elsevier Limited Aug 2009 |
Copyright_xml | – notice: Elsevier Inc. – notice: 2009 Elsevier Inc. – notice: 2009 INIST-CNRS – notice: Copyright Elsevier Limited Aug 2009 |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION K9. NAPCQ 7X8 |
DOI | 10.1016/j.ajo.2009.03.006 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1879-1891 |
EndPage | 271 |
ExternalDocumentID | 3556496781 10_1016_j_ajo_2009_03_006 19427616 21797660 S0002939409001615 1_s2_0_S0002939409001615 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | California |
GeographicLocations_xml | – name: California |
GroupedDBID | --- --K --M -~X .1- .55 .FO .GJ .~1 0R~ 1B1 1CY 1P~ 1~. 1~5 23M 3V. 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 7RV 7X7 8FI 8P~ AABNK AACTN AAEDT AAEDW AAHTB AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAWTL AAXKI AAXUO ABBQC ABCQX ABFNM ABFRF ABJNI ABLJU ABMAC ABMZM ABOCM ABPEJ ABXDB ACDAQ ACGFO ACGFS ACIUM ACNCT ACRLP ADBBV ADEZE ADFRT ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFJKZ AFKRA AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHMBA AI. AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN AZQEC BENPR BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 EBS EFJIC EJD EMOBN EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q G8K GBLVA GUQSH HVGLF HZ~ IHE J1W J5H K-O KOM L7B M1P M2O M41 MO0 N4W N9A O-L O9- OAUVE OF- OPF OQ~ OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 R2- RIG ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSZ SV3 T5K UNMZH UV1 VH1 WH7 WOW X7M XPP Z5R ZGI ZXP ~G- AAIAV ABLVK ABYKQ AHPSJ AJBFU EFLBG LCYCR ZA5 08R AAPBV AAUGY ABPIF ABPTK IQODW CGR CUY CVF ECM EIF NPM AAYXX ABDPE CITATION K9. NAPCQ 7X8 |
ID | FETCH-LOGICAL-c530t-60155bb665d897eef9b881f4cecc37b2beb6f84cb84f51140e5ee4b0db2f760b3 |
ISSN | 0002-9394 |
IngestDate | Fri Oct 25 02:04:25 EDT 2024 Thu Oct 10 21:48:05 EDT 2024 Thu Nov 21 23:13:40 EST 2024 Sat Sep 28 07:46:13 EDT 2024 Sun Oct 22 16:05:39 EDT 2023 Fri Feb 23 02:24:30 EST 2024 Tue Oct 15 14:37:43 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Thickness High Definition Macula Ophthalmology Optical coherence tomography |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c530t-60155bb665d897eef9b881f4cecc37b2beb6f84cb84f51140e5ee4b0db2f760b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 19427616 |
PQID | 1645004717 |
PQPubID | 41749 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_67505520 proquest_journals_1645004717 crossref_primary_10_1016_j_ajo_2009_03_006 pubmed_primary_19427616 pascalfrancis_primary_21797660 elsevier_sciencedirect_doi_10_1016_j_ajo_2009_03_006 elsevier_clinicalkeyesjournals_1_s2_0_S0002939409001615 |
PublicationCentury | 2000 |
PublicationDate | 2009-08-01 |
PublicationDateYYYYMMDD | 2009-08-01 |
PublicationDate_xml | – month: 08 year: 2009 text: 2009-08-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States – name: Chicago |
PublicationTitle | American journal of ophthalmology |
PublicationTitleAlternate | Am J Ophthalmol |
PublicationYear | 2009 |
Publisher | Elsevier Inc Elsevier Elsevier Limited |
Publisher_xml | – name: Elsevier Inc – name: Elsevier – name: Elsevier Limited |
References | Konno, Akiba, Yoshida (bib10) 2001; 21 Alam, Zawadzki, Choi (bib7) 2006; 113 Chan, Duker, Ko (bib9) 2006; 124 Forooghian, Cukras, Meyerle (bib15) 2008; 49 Hee, Puliafito, Wong (bib3) 1995; 113 Schaudig, Glaefke, Scholz, Richard (bib4) 2000; 31 Puliafito, Hee, Lin (bib2) 1995; 102 Lam, Chan, Mohamed (bib13) 2007; 114 Kelty, Payne, Trivedi (bib18) 2008; 49 Chew, Strauber, Beck (bib14) 2007; 114 Sanchez-Tocino, Alvarez-Vidal, Maldonado (bib5) 2002; 43 Wojtkowski, Srinivasan, Fujimoto (bib6) 2005; 112 Srinivasan, Wojtkowski, Witkin (bib8) 2006; 113 Yamaike, Tsjikawa, Ota (bib16) 2008; 115 Massin, Erginay, Haouchine (bib11) 2002; 12 Fleckenstein, Charbel Issa, Martin Helb (bib17) 2008; 49 (bib12) 1991; 98 Huang, Swanson, Lin (bib1) 1991; 254 Chauhan, Marshall (bib19) 1999; 40 Chan (10.1016/j.ajo.2009.03.006_bib9) 2006; 124 Huang (10.1016/j.ajo.2009.03.006_bib1) 1991; 254 Alam (10.1016/j.ajo.2009.03.006_bib7) 2006; 113 Fleckenstein (10.1016/j.ajo.2009.03.006_bib17) 2008; 49 Hee (10.1016/j.ajo.2009.03.006_bib3) 1995; 113 Chew (10.1016/j.ajo.2009.03.006_bib14) 2007; 114 Puliafito (10.1016/j.ajo.2009.03.006_bib2) 1995; 102 Wojtkowski (10.1016/j.ajo.2009.03.006_bib6) 2005; 112 Chauhan (10.1016/j.ajo.2009.03.006_bib19) 1999; 40 Yamaike (10.1016/j.ajo.2009.03.006_bib16) 2008; 115 Kelty (10.1016/j.ajo.2009.03.006_bib18) 2008; 49 Schaudig (10.1016/j.ajo.2009.03.006_bib4) 2000; 31 Konno (10.1016/j.ajo.2009.03.006_bib10) 2001; 21 Massin (10.1016/j.ajo.2009.03.006_bib11) 2002; 12 (10.1016/j.ajo.2009.03.006_bib12) 1991; 98 Forooghian (10.1016/j.ajo.2009.03.006_bib15) 2008; 49 Sanchez-Tocino (10.1016/j.ajo.2009.03.006_bib5) 2002; 43 Srinivasan (10.1016/j.ajo.2009.03.006_bib8) 2006; 113 Lam (10.1016/j.ajo.2009.03.006_bib13) 2007; 114 |
References_xml | – volume: 43 start-page: 1588 year: 2002 end-page: 1594 ident: bib5 article-title: Retinal thickness study with optical coherence tomography in patients with diabetes publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Maldonado – volume: 112 start-page: 1734 year: 2005 end-page: 1746 ident: bib6 article-title: Three-dimensional retinal imaging with high-speed ultra-high resolution optical coherence tomography publication-title: Ophthalmology contributor: fullname: Fujimoto – volume: 254 start-page: 1178 year: 1991 end-page: 1181 ident: bib1 article-title: Optical coherence tomography publication-title: Science contributor: fullname: Lin – volume: 102 start-page: 217 year: 1995 end-page: 229 ident: bib2 article-title: Imaging of macular diseases with optical coherence tomography publication-title: Ophthalmology contributor: fullname: Lin – volume: 21 start-page: 57 year: 2001 end-page: 61 ident: bib10 article-title: Retinal thickness measurements with optical coherence tomography and the retinal thickness analyzer publication-title: Retina contributor: fullname: Yoshida – volume: 98 start-page: 741 year: 1991 end-page: 756 ident: bib12 article-title: ETDRS Report No. 7: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics publication-title: Ophthalmology – volume: 115 start-page: 355 year: 2008 end-page: 362 ident: bib16 article-title: Three-dimensional imaging of cystoid macular edema in retinal vein occlusion publication-title: Ophthalmology contributor: fullname: Ota – volume: 113 start-page: 1425 year: 2006 end-page: 1431 ident: bib7 article-title: Clinical application of rapid serial Fourier-domain optical coherence tomography for macular imaging publication-title: Ophthalmology contributor: fullname: Choi – volume: 113 start-page: 1019 year: 1995 end-page: 1029 ident: bib3 article-title: Quantitative assessment of macular edema with optical coherence tomography publication-title: Arch Ophthalmol contributor: fullname: Wong – volume: 114 start-page: 2162 year: 2007 end-page: 2167 ident: bib13 article-title: Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema publication-title: Ophthalmology contributor: fullname: Mohamed – volume: 40 start-page: 2332 year: 1999 end-page: 2342 ident: bib19 article-title: The interpretation of optical coherence tomography images of the retina publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Marshall – volume: 113 start-page: 2054 year: 2006 end-page: 2065 ident: bib8 article-title: High-definition and 3-dimensional imaging of macular pathologies with high-speed ultra-high resolution optical coherence tomography publication-title: Ophthalmology contributor: fullname: Witkin – volume: 49 start-page: 2668 year: 2008 end-page: 2672 ident: bib18 article-title: Macular thickness assessment in healthy eyes based on ethnicity using Stratus optical coherence tomography publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Trivedi – volume: 124 start-page: 193 year: 2006 end-page: 198 ident: bib9 article-title: Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography publication-title: Arch Ophthalmol contributor: fullname: Ko – volume: 114 start-page: 1190 year: 2007 end-page: 1196 ident: bib14 article-title: Diabetic Retinopathy Clinical Research Network publication-title: Ophthalmology contributor: fullname: Beck – volume: 49 start-page: 4137 year: 2008 end-page: 4144 ident: bib17 article-title: High resolution spectral-domain OCT imaging in geographic atrophy associated with age-related macular degeneration publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Martin Helb – volume: 49 start-page: 4290 year: 2008 end-page: 4296 ident: bib15 article-title: Evaluation of time domain and spectral-domain optical coherence tomography in the measurement of diabetic macular edema publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Meyerle – volume: 31 start-page: 182 year: 2000 end-page: 186 ident: bib4 article-title: Optical coherence tomography for retinal thickness measurement in diabetic patients without clinically significant macular edema publication-title: Ophthalmic Surg Lasers contributor: fullname: Richard – volume: 12 start-page: 102 year: 2002 end-page: 108 ident: bib11 article-title: Retinal thickness in healthy and diabetic subjects measured using optical coherence tomography mapping software publication-title: Eur J Ophthalmol contributor: fullname: Haouchine – volume: 112 start-page: 1734 year: 2005 ident: 10.1016/j.ajo.2009.03.006_bib6 article-title: Three-dimensional retinal imaging with high-speed ultra-high resolution optical coherence tomography publication-title: Ophthalmology doi: 10.1016/j.ophtha.2005.05.023 contributor: fullname: Wojtkowski – volume: 102 start-page: 217 year: 1995 ident: 10.1016/j.ajo.2009.03.006_bib2 article-title: Imaging of macular diseases with optical coherence tomography publication-title: Ophthalmology doi: 10.1016/S0161-6420(95)31032-9 contributor: fullname: Puliafito – volume: 98 start-page: 741 year: 1991 ident: 10.1016/j.ajo.2009.03.006_bib12 article-title: ETDRS Report No. 7: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics publication-title: Ophthalmology doi: 10.1016/S0161-6420(13)38009-9 – volume: 21 start-page: 57 year: 2001 ident: 10.1016/j.ajo.2009.03.006_bib10 article-title: Retinal thickness measurements with optical coherence tomography and the retinal thickness analyzer publication-title: Retina doi: 10.1097/00006982-200102000-00010 contributor: fullname: Konno – volume: 115 start-page: 355 year: 2008 ident: 10.1016/j.ajo.2009.03.006_bib16 article-title: Three-dimensional imaging of cystoid macular edema in retinal vein occlusion publication-title: Ophthalmology doi: 10.1016/j.ophtha.2007.04.052 contributor: fullname: Yamaike – volume: 124 start-page: 193 year: 2006 ident: 10.1016/j.ajo.2009.03.006_bib9 article-title: Normal macular thickness measurements in healthy eyes using Stratus optical coherence tomography publication-title: Arch Ophthalmol doi: 10.1001/archopht.124.2.193 contributor: fullname: Chan – volume: 12 start-page: 102 year: 2002 ident: 10.1016/j.ajo.2009.03.006_bib11 article-title: Retinal thickness in healthy and diabetic subjects measured using optical coherence tomography mapping software publication-title: Eur J Ophthalmol doi: 10.1177/112067210201200205 contributor: fullname: Massin – volume: 254 start-page: 1178 year: 1991 ident: 10.1016/j.ajo.2009.03.006_bib1 article-title: Optical coherence tomography publication-title: Science doi: 10.1126/science.1957169 contributor: fullname: Huang – volume: 40 start-page: 2332 year: 1999 ident: 10.1016/j.ajo.2009.03.006_bib19 article-title: The interpretation of optical coherence tomography images of the retina publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Chauhan – volume: 49 start-page: 4290 year: 2008 ident: 10.1016/j.ajo.2009.03.006_bib15 article-title: Evaluation of time domain and spectral-domain optical coherence tomography in the measurement of diabetic macular edema publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.08-2113 contributor: fullname: Forooghian – volume: 43 start-page: 1588 year: 2002 ident: 10.1016/j.ajo.2009.03.006_bib5 article-title: Retinal thickness study with optical coherence tomography in patients with diabetes publication-title: Invest Ophthalmol Vis Sci contributor: fullname: Sanchez-Tocino – volume: 114 start-page: 2162 year: 2007 ident: 10.1016/j.ajo.2009.03.006_bib13 article-title: Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema publication-title: Ophthalmology doi: 10.1016/j.ophtha.2007.02.006 contributor: fullname: Lam – volume: 113 start-page: 2054 year: 2006 ident: 10.1016/j.ajo.2009.03.006_bib8 article-title: High-definition and 3-dimensional imaging of macular pathologies with high-speed ultra-high resolution optical coherence tomography publication-title: Ophthalmology doi: 10.1016/j.ophtha.2006.05.046 contributor: fullname: Srinivasan – volume: 49 start-page: 2668 year: 2008 ident: 10.1016/j.ajo.2009.03.006_bib18 article-title: Macular thickness assessment in healthy eyes based on ethnicity using Stratus optical coherence tomography publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.07-1000 contributor: fullname: Kelty – volume: 113 start-page: 1425 year: 2006 ident: 10.1016/j.ajo.2009.03.006_bib7 article-title: Clinical application of rapid serial Fourier-domain optical coherence tomography for macular imaging publication-title: Ophthalmology doi: 10.1016/j.ophtha.2006.03.020 contributor: fullname: Alam – volume: 49 start-page: 4137 year: 2008 ident: 10.1016/j.ajo.2009.03.006_bib17 article-title: High resolution spectral-domain OCT imaging in geographic atrophy associated with age-related macular degeneration publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.08-1967 contributor: fullname: Fleckenstein – volume: 113 start-page: 1019 year: 1995 ident: 10.1016/j.ajo.2009.03.006_bib3 article-title: Quantitative assessment of macular edema with optical coherence tomography publication-title: Arch Ophthalmol doi: 10.1001/archopht.1995.01100080071031 contributor: fullname: Hee – volume: 114 start-page: 1190 year: 2007 ident: 10.1016/j.ajo.2009.03.006_bib14 article-title: Diabetic Retinopathy Clinical Research Network publication-title: Ophthalmology contributor: fullname: Chew – volume: 31 start-page: 182 year: 2000 ident: 10.1016/j.ajo.2009.03.006_bib4 article-title: Optical coherence tomography for retinal thickness measurement in diabetic patients without clinically significant macular edema publication-title: Ophthalmic Surg Lasers doi: 10.3928/1542-8877-20000501-04 contributor: fullname: Schaudig |
SSID | ssj0006747 |
Score | 2.4819977 |
Snippet | Purpose To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal... To establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal disease.... PURPOSETo establish normative data for the macular thickness by spectral-domain optical coherence tomography (SD-OCT) in subjects with no known retinal... |
SourceID | proquest crossref pubmed pascalfrancis elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 266 |
SubjectTerms | Adult Age Aged Aged, 80 and over Aging - physiology Biological and medical sciences Body Weights and Measures Diabetes Diabetic retinopathy Female Fourier Analysis Humans Intraocular Pressure - physiology Macula Lutea - anatomy & histology Male Medical sciences Middle Aged Miscellaneous Ophthalmology Prospective Studies Reference Values Standard deviation Tomography, Optical Coherence - methods Visual Acuity - physiology Young Adult |
Title | Normative Data for Macular Thickness by High-Definition Spectral-Domain Optical Coherence Tomography (Spectralis) |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S0002939409001615 https://dx.doi.org/10.1016/j.ajo.2009.03.006 https://www.ncbi.nlm.nih.gov/pubmed/19427616 https://www.proquest.com/docview/1645004717 https://search.proquest.com/docview/67505520 |
Volume | 148 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6ISEkhPimMIYfeACqVInj2MkjWguTpg2JlgnxYtmJo6Zd09IPJP57znG-2mkIkHhJK8d13Px-vjvb5zuEXitfppz7xEm8VDnUS2JH-QCIlMSLiadJEJuzw6cjfvE1HAzpsNOp8rg2Zf8VaSgDrM3J2b9Au24UCuA7YA5XQB2uf4T7hTVCjT-Q3MjCi_BcWmfT8SSLZ4VoA5vTOHg4A51meWaFhjlyuZJXzmAxl1ne-7S0q9zm_IaNRDtezMv41sYsreqbGAVR28St94BaQSkWy8lmIq_mO2v4H1eV--jIrGTrZQv8TQm-_JH1zvqtjf-i_mU2W8l5b1TfOIHGLbPP5Mw48PYu-zvrGVHtTVcuslUHbXb8QAvBHfk2H3JfW1kd8sjxQpvsqxbmNGyxlrRFM2MtLU9s4pdrCsSuZUz7croog5maCLh7wboL9T8yfTJdciNrNx-gWwSknRG234LPtTnAOOXVHMxUr7bWCyfDvcfcZBzdXco1QJ7aXCs3T4YKo2h8H90rZzP4vaXhA9TR-UN0-7z013iEvtdsxIaNGNiISzbimo1Y_cR7bMR7bMQlG3HNRtywEb9puPj2MfryYTg-OXXKJB9OHPjuxmHGaFeKsSAJI651Gqkw9FIag2zxuSJKK5aGNFYhTWFyQF0daE2VmyiScuYq_wk6zBe5foYwTeIQJvzUk_BBZSyDNPQl01Ap0Vx7XfSuertiaWO5iMrJcSoACpOTNRKuLwCKLuLV-xfVIWVQq3pdDp618MSaCFdc40EX0fqXpRlrzVMBJPvdA493UK67SEBncsbcLjqqYBdNJxgNTMRXj3fRq_o2qAiz7ydzvdiuBYNZQRAQaOCpJUvz7yNKOPPY83_r8gt0pxnBR-hws9rql-hgnWyPizHwC_lc6AM |
link.rule.ids | 315,782,786,27933,27934 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Normative+Data+for+Macular+Thickness+by+High-Definition+Spectral-Domain+Optical+Coherence+Tomography+%28Spectralis%29&rft.jtitle=American+journal+of+ophthalmology&rft.au=Grover%2C+Sandeep&rft.au=Murthy%2C+Ravi+K.&rft.au=Brar%2C+Vikram+S.&rft.au=Chalam%2C+Kakarla+V.&rft.date=2009-08-01&rft.pub=Elsevier+Inc&rft.issn=0002-9394&rft.eissn=1879-1891&rft.volume=148&rft.issue=2&rft.spage=266&rft.epage=271&rft_id=info:doi/10.1016%2Fj.ajo.2009.03.006&rft.externalDocID=S0002939409001615 |
thumbnail_m | http://sdu.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00029394%2FS0002939409X00073%2Fcov150h.gif |